The study will evaluate safety and efficacy of a 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Recruiting
Phase 1/Phase 2
Background:
T cells modified with lentiviral chimeric antigen receptor (CAR) gene have been studied in
different clinical settings. Recent successes suggest that increased costimulatory signaling
in the CAR design is critical for long term efficacy. Activation of T cell response from
large tumor burden may induce a severe response. To increase safety, a novel design using an
inducible caspase 9 fusion gene has been incorporated in the CAR gene. A 4th generation CAR
lentiviral vector (4SCAR) carrying T cell costimulatory signals for CD28/CD27 plus an
inducible apoptotic caspase 9 gene has been established. The study aims to evaluate the
activities of a new CAR gene-modified T cells targeting CD19-positive tumors based on a
CD19-specific single chain gene constructed 4SCAR (4SCAR19).
Objective:
To evaluate safety and efficacy of administrating 4SCAR19 T cells to patients with CD19
positive B cell malignancies following a cyclophosphamide/fludarabine based conditioning
regimen.
Eligibility:
Patients older than 6-month-old with CD19 positive B cells malignancies that have recurred
after or refractory to standard therapy and is deemed incurable using standard treatment.
Design:
Participants will be screened based on cancer cell phenotype analyzed using flow cytometry or
immunohistochemical staining methods.
Peripheral blood mononuclear cells (PBMC) will be obtained through apheresis, and T cells
will be activated and modified to express the 4SCAR19 gene.
On Day -5 to -7, PBMC will be activated and enriched for T cells, which will be followed by
4SCAR19 lentiviral transduction. The total cell preparation time is approximately 5-7 days.
Participants will receive a preparative conditioning regimen comprising
cyclophosphamide/fludarabine to prepare their immune system to accommodate the modified CAR T
cells. The preparative regimen will be based on patient immune condition and consistent with
standard chemotherapy conditioning regimen.
Participants will receive an infusion of the modified 4SCAR19 T cells and closely followed up
for treatment-related responses.
Participants will be continuously monitored for CAR T cells and clinical responses at present
timeline.
| Name | Type | Description | Interventions |
|---|---|---|---|
| Therapeutic 4SCAR19 cells | Experimental | Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells. |
Inclusion Criteria:
1. aged more than 6 months.
2. malignant B cell surface expression CD19 molecules.
3. the KPS score over 80 points, and survival time is more than 3 months.
4. greater Hgb 80 g/L.
5. no contraindications to solid and cell separation
Exclusion Criteria:
1. accompanied with other active diseases, the treatment is difficult to correct.
2. bacteria, fungus, or virus infection, unable to control.
3. people living with HIV.
4. active HBV and HCV infection.
5. of pregnancy and nursing mothers.
6. before entering the test of the use of glucocorticoid systemic treatment within a
week.
7. confirmed before used CAR - but invalid
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 6 Months |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
| Measure: | Safety of fourth generation anti CD19 CAR-T cells in patients with relapsed B cell malignancies using CTCAE 4 standard to evaluate the level of adverse events |
| Time Frame: | 24 weeks |
| Safety Issue: | |
| Description: | physiological parameter (for safety, measuring cytokine response, fever, symptoms) |
| Measure: | Anti tumor activity of fourth generation anti CD19 CAR-T cells in patients with relapsed or refractory B cell malignancies |
| Time Frame: | 1 year |
| Safety Issue: | |
| Description: | scale of CAR copies and leukemic cell burden (for efficacy) |
| Phase: | Phase 1/Phase 2 |
| Primary Purpose: | Interventional |
| Overall Status: | Recruiting |
| Lead Sponsor: | Shenzhen Geno-Immune Medical Institute |
September 19, 2019
